Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients

PURPOSE: To assess the overall survival (OS) and progression-free survival (PFS) of unresectable hepatocellular carcinoma (HCC) patients undergoing yttrium-90 glass–microsphere transarterial radioembolization (TARE) with and without concurrent sorafenib. METHODS: OS and PFS were analyzed in 55 patie...

Full description

Saved in:
Bibliographic Details
Published in:J Hepatocell Carcinoma
Main Authors: Teyateeti, Ajalaya, Mahvash, Armeen, Long, James P, Abdelsalam, Mohamed E, Avritscher, Rony, Chasen, Beth, Kaseb, Ahmed O, Kuban, Joshua D, Murthy, Ravi, Odisio, Bruno C, Teyateeti, Achiraya, Macapinlac, Homer A, Kappadath, S Cheenu
Format: Artigo
Language:Inglês
Published: Dove 2020
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7500841/
https://ncbi.nlm.nih.gov/pubmed/32984089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S248314
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items